Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Nov;27(11):e183-e184.
doi: 10.1097/IJG.0000000000001063.

Brinzolamide-induced Follicular Conjunctivitis

Jonathan W Young  1 , John L Clements  1 , John C Morrison  1 , Hana L Takusagawa  1   2
Affiliations
Case Reports

Brinzolamide-induced Follicular Conjunctivitis

Jonathan W Young et al. J Glaucoma. 2018 Nov.

Abstract

We report a case of a patient who developed a severe case of follicular conjunctivitis from brinzolamide after 1.5 years of consistent use. This patient was rechallenged again after resolution of the follicles and subsequently redeveloped similar conjunctivitis. This is the first confirmed reported case of follicular conjunctivitis from brinzolamide use.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
(A) Severe inferior palpebral follicular response after 1.5 years of topical brinzolamide 1% applied twice daily in both eyes. (B) Resolution of follicular response after stopping brinzolamide.
See this image and copyright information in PMC

References

    1. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002;11(2):119–26. - PubMed
    1. Fraunfelder FT, Fraunfelder FW, Chambers WA. Clinical Ocular Toxicology E-Book:Drug-Induced Ocular Side Effects: Elsevier Health Sciences, 2008.
    1. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol 1998;126(3):400–8. - PubMed
    1. March WF, Ochsner KI. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. Am J Ophthalmol 2000;129(2):136–43. - PubMed
    1. Manni G, Centofanti M, Sacchetti M, et al. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy. J Glaucoma 2004;13(2):163–7. - PubMed

Publication types